title: [The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery].
abstract: To evaluate the role of botulinum toxin type A in the acute phase of facial nerve injury after neurosurgical surgery.
  
  
  
  The study involved 55 patients with acute facial muscle paresis caused by facial nerve injury during surgery on the posterior cranial fossa and cerebello-pontine angle (CPA). The first group consisted of 35 patients (mean age, 48.14±1.26 years) who were administered botulinum toxin type A (xeomin) at a dose of 2-3 U per point in muscles of the intact side of the face. The control group included 20 patients (mean age, 49.85±1.4 years) who underwent standard rehabilitation treatment of this pathology. The treatment efficacy was evaluated using the House-Brackmann Scale, the Yanagihara facial grading system, the Facial Disability Index (FDI), and the Sunnybrook Facial Grading (SFG) Scale.
  
  
  
  Before treatment, patients of both groups experienced severe dysfunction according to the House-Brackmann Scale. A month after the botulinium toxin type A therapy had been started, a significant improvement in the group of patients who received botulinum toxin was observed at all scales (p<0.05), whereas improvement in the facial nerve function in the second group was observed only by the 3rd month of rehabilitation treatment (p<0.05). The number of synkineses in the patients who did not receive botulinum toxin was 46% higher than that in the first group (p=0.019) one year after the surgery, and it was higher by 91% after 2 years (p<0.001).
  
  
  
  The use of botulinum toxin type A is reasonable in acute facial nerve injury and should be mandatory in combined therapy of these patients.
authors: GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Sechenova" Minzdrava Rossii, Moskva; Tsentr mezhdistsiplinarnoĭ stomatologii i nevrologii, Moskva.
authors: O R
authors: OR
authors: Orlova
authors: FGBNU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva.
authors: M A
authors: MA
authors: Akulov
authors: FGBNU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva.
authors: D Iu
authors: DI
authors: Usachev
authors: FGBNU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva.
authors: S V
authors: SV
authors: Taniashin
authors: FGBNU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva.
authors: V O
authors: VO
authors: Zakharov
authors: Tsentr mezhdistsiplinarnoĭ stomatologii i nevrologii, Moskva.
authors: E V
authors: EV
authors: Saksonova
authors: Tsentr mezhdistsiplinarnoĭ stomatologii i nevrologii, Moskva.
authors: L R
authors: LR
authors: Mingazova
authors: Tsentr mezhdistsiplinarnoĭ stomatologii i nevrologii, Moskva.
authors: S V
authors: SV
authors: Surovykh
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D020220:Facial Nerve Injuries / Q000188:drug therapy* / Q000209:etiology; D005158:Facial Paralysis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D019635:Neurosurgical Procedures / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A